Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $29,658.24 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,878 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total value of $29,658.24. Following the completion of the transaction, the insider now owns 158,687 shares in the company, valued at approximately $964,816.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Sight Sciences Price Performance

Shares of NASDAQ:SGHT opened at $5.81 on Friday. The stock has a fifty day moving average of $6.46 and a 200-day moving average of $6.24. The company has a market capitalization of $292.30 million, a PE ratio of -5.19 and a beta of 2.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. Sight Sciences, Inc. has a one year low of $1.04 and a one year high of $8.45.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The business had revenue of $21.37 million for the quarter, compared to the consensus estimate of $21.32 million. During the same period last year, the firm posted ($0.30) earnings per share. As a group, equities analysts anticipate that Sight Sciences, Inc. will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on SGHT shares. Lake Street Capital started coverage on Sight Sciences in a report on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective for the company. Morgan Stanley upped their target price on Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a report on Monday, July 15th. Citigroup boosted their price objective on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research report on Wednesday, July 10th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.25.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors have recently bought and sold shares of SGHT. Vanguard Group Inc. increased its stake in shares of Sight Sciences by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after acquiring an additional 81,768 shares during the last quarter. Long Focus Capital Management LLC boosted its position in Sight Sciences by 86.9% during the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after purchasing an additional 260,594 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in shares of Sight Sciences by 25.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after acquiring an additional 76,549 shares during the period. B. Riley Wealth Advisors Inc. bought a new stake in shares of Sight Sciences in the second quarter valued at approximately $1,234,000. Finally, RTW Investments LP bought a new stake in shares of Sight Sciences in the fourth quarter valued at approximately $850,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.